Syncona Ltd notes further safety and enzyme activity data from its portfolio company, Freeline Therapeutics, on its gene therapy candidate for Gaucher disease...
Syncona Ltd notes further safety and enzyme activity data from its portfolio company, Freeline Therapeutics, on its gene therapy candidate for Gaucher disease...